BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 27211996)

  • 1. Patients' Beliefs About Medications are Associated with Stated Preference for Methadone, Buprenorphine, Naltrexone, or no Medication-Assisted Therapy Following Inpatient Opioid Detoxification.
    Uebelacker LA; Bailey G; Herman D; Anderson B; Stein M
    J Subst Abuse Treat; 2016 Jul; 66():48-53. PubMed ID: 27211996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial.
    Bisaga A; Mannelli P; Yu M; Nangia N; Graham CE; Tompkins DA; Kosten TR; Akerman SC; Silverman BL; Sullivan MA
    Drug Alcohol Depend; 2018 Jun; 187():171-178. PubMed ID: 29674251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Injectable Extended-Release Naltrexone Compared With Methadone Maintenance and Buprenorphine Maintenance Treatment for Opioid Dependence.
    Jackson H; Mandell K; Johnson K; Chatterjee D; Vanness DJ
    Subst Abus; 2015; 36(2):226-31. PubMed ID: 25775099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine.
    Sullivan M; Bisaga A; Pavlicova M; Choi CJ; Mishlen K; Carpenter KM; Levin FR; Dakwar E; Mariani JJ; Nunes EV
    Am J Psychiatry; 2017 May; 174(5):459-467. PubMed ID: 28068780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perceptions around medications for opioid use disorder among a diverse sample of U.S. adults.
    Jaffe K; Slat S; Chen L; Macleod C; Bohnert A; Lagisetty P
    J Subst Use Addict Treat; 2024 Aug; 163():209361. PubMed ID: 38703949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure.
    Shulman M; Choo TH; Scodes J; Pavlicova M; Wai J; Haenlein P; Tofighi B; Campbell ANC; Lee JD; Rotrosen J; Nunes EV
    J Subst Abuse Treat; 2021 May; 124():108292. PubMed ID: 33771287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare utilization and costs associated with treatment for opioid dependence.
    Shah A; Duncan M; Atreja N; Tai KS; Gore M
    J Med Econ; 2018 Apr; 21(4):406-415. PubMed ID: 29320915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial.
    Gustafson DH; Landucci G; McTavish F; Kornfield R; Johnson RA; Mares ML; Westergaard RP; Quanbeck A; Alagoz E; Pe-Romashko K; Thomas C; Shah D
    Trials; 2016 Dec; 17(1):592. PubMed ID: 27955689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.
    Lee JD; Nunes EV; Mpa PN; Bailey GL; Brigham GS; Cohen AJ; Fishman M; Ling W; Lindblad R; Shmueli-Blumberg D; Stablein D; May J; Salazar D; Liu D; Rotrosen J
    Contemp Clin Trials; 2016 Sep; 50():253-64. PubMed ID: 27521809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens.
    Comer SD; Mannelli P; Alam D; Douaihy A; Nangia N; Akerman SC; Zavod A; Silverman BL; Sullivan MA
    Am J Addict; 2020 Jul; 29(4):313-322. PubMed ID: 32246728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of Treatments for Opioid Use Disorder.
    Fairley M; Humphreys K; Joyce VR; Bounthavong M; Trafton J; Combs A; Oliva EM; Goldhaber-Fiebert JD; Asch SM; Brandeau ML; Owens DK
    JAMA Psychiatry; 2021 Jul; 78(7):767-777. PubMed ID: 33787832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of medication assisted treatment for opioid use in prison and jail settings: A meta-analysis and systematic review.
    Moore KE; Roberts W; Reid HH; Smith KMZ; Oberleitner LMS; McKee SA
    J Subst Abuse Treat; 2019 Apr; 99():32-43. PubMed ID: 30797392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of medication assisted treatment (MAT) for opioid use disorder on functional outcomes: A systematic review.
    Maglione MA; Raaen L; Chen C; Azhar G; Shahidinia N; Shen M; Maksabedian E; Shanman RM; Newberry S; Hempel S
    J Subst Abuse Treat; 2018 Jun; 89():28-51. PubMed ID: 29706172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Court personnel attitudes towards medication-assisted treatment: A state-wide survey.
    Andraka-Christou B; Gabriel M; Madeira J; Silverman RD
    J Subst Abuse Treat; 2019 Sep; 104():72-82. PubMed ID: 31370988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A qualitative assessment of attitudes about and preferences for extended-release naltrexone, a new pharmacotherapy to treat opioid use disorders in Ukraine.
    Marcus R; Bojko MJ; Mazhnaya A; Makarenko I; Filippovych S; Dvoriak S; Altice FL; Springer SA
    J Subst Abuse Treat; 2018 Mar; 86():86-93. PubMed ID: 29415856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance medication for opiate addiction: the foundation of recovery.
    Bart G
    J Addict Dis; 2012; 31(3):207-25. PubMed ID: 22873183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial.
    Lee JD; McDonald R; Grossman E; McNeely J; Laska E; Rotrosen J; Gourevitch MN
    Addiction; 2015 Jun; 110(6):1008-14. PubMed ID: 25703440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjunctive memantine for opioid use disorder treatment: A systematic review.
    Elias AM; Pepin MJ; Brown JN
    J Subst Abuse Treat; 2019 Dec; 107():38-43. PubMed ID: 31757263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women.
    Tran TH; Griffin BL; Stone RH; Vest KM; Todd TJ
    Pharmacotherapy; 2017 Jul; 37(7):824-839. PubMed ID: 28543191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.